HK1137028A1 - Phosphadiazine hcv polymerase inhibitors iv - Google Patents

Phosphadiazine hcv polymerase inhibitors iv

Info

Publication number
HK1137028A1
HK1137028A1 HK10104852.7A HK10104852A HK1137028A1 HK 1137028 A1 HK1137028 A1 HK 1137028A1 HK 10104852 A HK10104852 A HK 10104852A HK 1137028 A1 HK1137028 A1 HK 1137028A1
Authority
HK
Hong Kong
Prior art keywords
phosphadiazine
hcv polymerase
polymerase inhibitors
iva
formulas
Prior art date
Application number
HK10104852.7A
Other languages
English (en)
Inventor
Cyril Dousson
Dominique Surleraux
Jean-Laurent Paparin
Claire Pierra
Arlene Roland
Original Assignee
Idenix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Pharmaceuticals Inc filed Critical Idenix Pharmaceuticals Inc
Publication of HK1137028A1 publication Critical patent/HK1137028A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65848—Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10104852.7A 2007-08-31 2010-05-18 Phosphadiazine hcv polymerase inhibitors iv HK1137028A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96723707P 2007-08-31 2007-08-31
PCT/US2008/010225 WO2009032180A1 (en) 2007-08-31 2008-08-28 Phosphadiazine hcv polymerase inhibitors iv

Publications (1)

Publication Number Publication Date
HK1137028A1 true HK1137028A1 (en) 2010-07-16

Family

ID=39874081

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10104852.7A HK1137028A1 (en) 2007-08-31 2010-05-18 Phosphadiazine hcv polymerase inhibitors iv

Country Status (17)

Country Link
US (4) US20090060866A1 (xx)
EP (1) EP2183260B1 (xx)
JP (1) JP5514108B2 (xx)
KR (1) KR20100072002A (xx)
CN (1) CN101842378A (xx)
AT (1) ATE511514T1 (xx)
AU (1) AU2008296997B2 (xx)
BR (1) BRPI0815920A2 (xx)
CA (1) CA2697546A1 (xx)
ES (1) ES2367550T3 (xx)
HK (1) HK1137028A1 (xx)
MX (1) MX2010002296A (xx)
NZ (1) NZ583545A (xx)
RU (1) RU2483073C2 (xx)
TW (1) TW200927143A (xx)
UA (1) UA95715C2 (xx)
WO (4) WO2009032179A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
US10766917B2 (en) 2015-05-27 2020-09-08 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
GEP20237457B (en) 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
CN111233925B (zh) * 2018-11-28 2021-03-26 上海日馨生物科技有限公司 硫胺类化合物、制备方法及其药物组合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113698315A (zh) * 2021-09-03 2021-11-26 内蒙古蓝科生物科技有限公司 一种2-三氟甲基苯甲酰胺的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU495317A1 (ru) * 1973-11-14 1975-12-15 Киевский научно-исследовательский институт фармакологии и токсикологии Способ получени этилениминопроизводных 1,2,6-фосфадиазинов
MXPA01008937A (es) * 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
EP1634886A3 (en) 1999-03-05 2006-03-29 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrug
AU4329000A (en) * 1999-04-19 2000-11-02 G.D. Searle & Co. Novel heterocyclic amino carbonyl derivatives useful as nitric oxide synthase inhibitors
WO2003099801A1 (en) * 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
EP1786807B1 (en) * 2004-08-23 2009-07-29 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
DE602007011213D1 (de) * 2006-02-17 2011-01-27 Hoffmann La Roche Heterocyclische antivirale verbindungen

Also Published As

Publication number Publication date
AU2008296997A1 (en) 2009-03-12
RU2483073C2 (ru) 2013-05-27
US20090081158A1 (en) 2009-03-26
ATE511514T1 (de) 2011-06-15
US20090060872A1 (en) 2009-03-05
NZ583545A (en) 2011-04-29
US20090060866A1 (en) 2009-03-05
WO2009032176A1 (en) 2009-03-12
WO2009032179A1 (en) 2009-03-12
KR20100072002A (ko) 2010-06-29
UA95715C2 (ru) 2011-08-25
EP2183260A1 (en) 2010-05-12
BRPI0815920A2 (pt) 2015-02-18
WO2009032180A1 (en) 2009-03-12
CN101842378A (zh) 2010-09-22
MX2010002296A (es) 2010-04-01
JP5514108B2 (ja) 2014-06-04
US20090060867A1 (en) 2009-03-05
EP2183260B1 (en) 2011-06-01
JP2010537986A (ja) 2010-12-09
US7932240B2 (en) 2011-04-26
WO2009032177A1 (en) 2009-03-12
RU2010112408A (ru) 2011-10-10
CA2697546A1 (en) 2009-03-12
ES2367550T3 (es) 2011-11-04
AU2008296997B2 (en) 2013-08-29
TW200927143A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
HK1137028A1 (en) Phosphadiazine hcv polymerase inhibitors iv
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
GEP20125511B (en) Mapk/erk kinase inhibitors
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
PH12014500053A1 (en) Proteasome inhibitors
MY148534A (en) Inhibitors of human immunodeficiency virus replication
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
UA99284C2 (xx) ІНГІБІТОРИ р70 S6-КІНАЗИ$ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
CL2008001740A1 (es) Compuestos derivados de piperidinas sustituidas, inhibidores de la dna-girasa y/o topoisomerasa iv; procedimeinto para su preparacion; composiicon farmaceutica que comprende estos compustos y su uso en el tratamiento de una infeccion bacteriana.
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2010101967A3 (en) Phosphothiophene and phosphothiazole hcv polymerase inhibitors
BR112013028679A2 (pt) inibidores do vírus da hepatite c
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
WO2012061248A3 (en) Novel specific hcv ns3 protease inhibitors
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170828